Beth Fand Incollingo

Articles

New ASCO/CCO mCRPC Treatment Guideline Incorporates Latest Approved Drugs

September 8th 2014

ASCO and CCO have released an updated guideline focused on the treatment of men with mCRPC that incorporates information about 6 recently approved drugs that have significantly changed the therapeutic landscape.

Latest Evidence Guides Use of ADT with RT in Prostate Cancer

September 4th 2014

Practice-changing trends in the combined use of androgen deprivation therapy (ADT) and radiation therapy (RT) for the treatment of prostate cancer were highlighted recently in a review paper by Mack Roach III, MD, a professor of Radiation Oncology and Urology and chair of the Department of Radiation Oncology at the University of California, San Francisco.

"Angelina Jolie Effect" Sparks More BRCA Testing at Cancer Center

September 2nd 2014

The actress Angelina Jolie's decision to undergo a preventive double mastectomy after learning she carried the BRCA1 gene mutation-associated with an increased risk of breast and/or ovarian cancer-apparently sparked an "Angelina effect" on public health.

Enzalutamide + Sipuleucel-T Gives Immune Boost in mCRPC

September 1st 2014

Sipuleucel-T (Provenge), an immunotherapy tailor-made for men with metastatic castration-resistant prostate cancer (mCRPC) using their own white blood cells, is just as potent if it is manufactured while a patient is taking enzalutamide (Xtandi), and the two drugs seem to boost immunity more effectively when administered together.

Urology Clinics Must Lead Way in Preventing Workplace Violence

August 29th 2014

It took just a minute and a half for a disgruntled patient to leave his deadly mark on a Nevada urology clinic, irreversibly changing the lives of everyone inside.

Sipuleucel-T Helps ADT Boost Prostate Cancer Immunity

August 28th 2014

Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a study has found.

Urologist Perspectives Affect Treatments for Prostate Cancer

August 26th 2014

A physician's perspective, and the therapies he most often prescribes, can have a big influence on whether his patients with low-risk prostate cancer are treated or put on active surveillance, a study has found.

Prostate Cancer in Younger Men a Separate Phenotype

August 22nd 2014

Prostate cancer that emerges when a man is 55 years of age or younger is a distinct phenotype of the disease, and should be treated and researched accordingly,

Genes That Drive Clear-Cell RCC Discovered, Providing Research Clues

August 21st 2014

A genomic analysis of renal cell carcinoma (RCC) has uncovered new clues about the development, growth, and spread of the cancer.

In 2 Cancers, Robotic Versus Open Surgery is Explored

August 20th 2014

In recent studies, robotic-assisted surgery was explored as a treatment for both prostate and kidney cancers.

In Prostate Cancer, Depression Means Less Treatment, Worse Outcomes

August 19th 2014

Men diagnosed with prostate cancer after being diagnosed with depression were less likely to undergo definitive treatment for their cancer and had worse overall survival.

Two-Part Series to Explore Use of Biomarkers in GU Cancer Treatment

August 12th 2014

When it comes to the personalized treatment of genitourinary cancers, biomarkers hold an immense amount of promise. Already, there are predictive and prognostic tools available to urologists.

AUA Adds Radium-223 to Treatment Guidelines for mCRPC

August 6th 2014

The American Urological Association (AUA) has added recommendations for the use of radium-223 to its treatment guidelines for castration-resistant prostate cancer

Herbst Tackles Key Questions in Emerging PD-1/PD-L1 Immunotherapy for NSCLC

August 2nd 2014

Emerging agents and pressing research questions in immunotherapy were reviewed in depth during the 15th Annual International Lung Cancer Congress, with Roy S. Herbst, MD, PhD, of the Yale Cancer Center, leading the way.

TKIs Combined With Other Drugs May Prove More Effective in NSCLC

August 1st 2014

Tyrosine kinase inhibitors (TKIs) are effective as single agents in EGFR-positive non-small cell lung cancer (NSCLC), but investigators continue to ask questions about how to improve the results of these agents.

Experimental Drugs Hit KRAS and Downstream Targets in NSCLC

August 1st 2014

The KRAS mutation in lung cancer is an especially thorny problem, as it is an indicator of a poor prognosis and has not, in the past, been targeted specifically by any medications.

CT Screening for Lung Cancer an Important Life-Saving Tool

July 31st 2014

When the US Preventive Services Task Force (USPSTF) recommended last year that asymptomatic, high-risk individuals should receive annual screening for lung cancer with low-dose computed tomography (LDCT), it made a healthy decision for the American population

Lung Congress to Offer Thorough Review of Latest Research Findings

July 31st 2014

The 15th Annual International Lung Cancer Congress, which began today in Huntington Beach, California and will continue through Saturday, will offer an array of information presented by multidisciplinary experts-in a brand-new format.

Advanced Prostate Cancer Clinics Keep Urologists, Patients Together

July 10th 2014

When a patient develops advanced prostate cancer, that doesn't mean his urologist needs to bid him farewell.

Radium-223, Abiraterone to be Studied in Combination

July 9th 2014

Two recently approved drugs for the treatment of advanced prostate cancer-radium-223 (Xofigo) and abiraterone acetate (Zytiga)-will be studied in combination in a phase III clinical trial.